Page 22 - Cipla

Cipla takes a cautious approach towards tender business to protect margins

Tender business, which accounts for around 20% of consolidated sales, came under pressure because of intense competition and aggressive pricing

Cipla records sharpest fall in one year post Q2 results; stock down 8%

The stock has dipped 8% to Rs 558 on the BSE after the pharmaceutical company posted 11% decline in its consolidated net profit at Rs 3.77 billion for Q2FY19.

Cipla gets final nod for generic version of Aralez's Toprol Xl ER tablets

Cipla's Metoprolol ER Tablets 50mg, 100mg, 200mg is AB-rated beta1-selective adrenoceptor blocking agent

Cipla plans expansion, aims to launch at least one product in US every year

In India, the company is by far the leader in the respiratory drugs segment, having a turnover of over Rs 18.93 billion

We are determined to make fearless living a habit: Cipla's Umang Vohra

'We are looking to provide end-to-end solutions in the area of disease management for Patients'

Cipla nears its 52-week high post Q1 results

The stock has rallied 4.6% to Rs 662 on the BSE in early morning trade, trading close to its 52-week high of Rs 663 touched on November 11, 2017.

Cipla plans acquisitions to enter new therapies, boost Africa business

The company is looking at inorganic growth opportunities to offset delays in product approvals

Cipla acquires 100% stake in South African pharmaceutical company Mirren

The transaction is subject to the approval by the Competition Commission of South Africa

Cipla gains 3% post USFDA approval for its generic HIV drug

The stock up 3% at Rs 622 on the BSE in early morning trade and is 6.6% away from its 52-week high of Rs 663 touched on November 7, 2017.

Cipla surges 7% post March quarter results

The stock surged 7% to Rs 563, bouncing back 8% from its early morning low of Rs 520 on the BSE.

Cipla arm recalls multiple lots of antidepressant drug from US market

The report, however, did not mention the quantity of the product

Cipla stock: Healthy momentum in sales indicates strong earnings visibility

Cipla's relatively late entry into the US market is proving a blessing

Cipla rebounds after clarification on USFDA observations for Goa unit

The stock moved higher to Rs 558, bouncing back 7% from its early morning low of Rs 523 on the BSE.

Pricing woes force Cipla, Glenmark, Lupin to go slow on US drug pipeline

Companies to focus on complex products as tough competition in generics, customer consolidation impact profits

Cipla gains 7% on healthy operational performance in Q3

The stock surged 7% to Rs 608 after the EBITDA margins in December quarter improved to 20.9% from 18.6% in year ago quarter and 19.7% in previous quarter.

Cipla stands out in a gloomy sector as revenue swells 15% to Rs 16 bn

Improving prospects of US business to drive the company's earnings

Business for posterity

Companies must create value through transformational impact on the planet

Cipla battles perceptions in a new campaign

The pharma major engages directly with patients, addresses social stigma and environmental concerns to expand the brand footprint in respiratory diseases

Cipla shines in gloomy pharma pack, biggest beneficiary of faster approvals

A low base in the US also means lower risks of price erosion, but as the company builds up its product pipeline expect earnings to improve

Cipla gets USFDA nod to market generic version of cancer drug Dacogen

It is indicated for treatment of patients with myelodysplastic syndromes